This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks' treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels. Body weight, SBP and triglyceride levels were reduced across most respective subgroups, with no significant subgroup-bytreatment interactions. For each treatment, weight loss was numerically greater as baseline body mass index increased. SBP reductions were greater among patients with SBP ≥140 vs <140 mm Hg for exenatide once weekly plus dapagliflozin and exenatide once weekly. Reductions in triglyceride levels were greater among patients with baseline triglycerides <1.69 vs ≥1.69 mmol/L for each treatment. The combination of exenatide once weekly plus dapagliflozin reduced cardiovascular risk factors across baseline subgroups for each variable to a greater extent than did either individual drug; the greatest effects were observed in the high baseline subgroups for body weight and SBP.
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| Patients
Demographics and patient characteristics at baseline were generally similar across treatment groups, as previously reported. 6 Patient subgroups were based on clinically relevant thresholds for each cardiovascular risk factor at baseline; the repartition of patients in each subgroup is shown in Table 1 .
| Body weight
At baseline, mean body weight in the exenatide once weekly plus dapa- patients receiving exenatide once weekly (−1.56 AE 0.29 kg; P < .001) or dapagliflozin (−2.22 AE 0.28 kg; P < .001). 6 In the baseline BMI subgroup analyses, patients in the overweight and obese subgroups lost weight with all tested treatments ( Figure 1A A limitation of the present analysis is the small sample size of some of the subpopulations, which may limit the interpretation of the results. Additional limitations include the post hoc nature of the assessment and the lack of correction for multiplicity.
| DISCUSSION
In conclusion, in patients with T2DM with inadequate glycaemic control on metformin alone, adding a combination of exenatide once weekly plus dapagliflozin reduced cardiovascular risk factors across baseline subgroups for each variable to a greater extent than adding either individual drug. The greatest effects were observed in the high baseline subgroups for body weight and SBP and the lower baseline subgroup for triglycerides.
